The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Biotech companies Abacus Diagnostica, Kaivogen, and Labrox announced Tuesday that they are combining to create an in vitro diagnostics firm to develop near-patient antibody and PCR tests for infectious diseases and cancers that could be run from a single device.

Mesa Laboratories said on Tuesday that it has acquired mass spectrometry-based genetic analysis firm Agena Bioscience for $300 million in cash.

On September 16, Beijing Hotgen Biotech Co.,Ltd. stated that the company proposed to establish Beijing Yaojing Gene Technology Co., Ltd. with a joint investment of CNY100 million with Mr. LIN Changqing (Chairman of Hotgen) and Beijing Yaojing Enterprise Management Center.

Ginkgo Bioworks said on Tuesday that it has completed its merger with special purpose acquisition company Soaring Eagle Acquisition and that its stock will start to trade publicly on the New York Stock Exchange on Friday.

Cepheid announced on Tuesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a new version of its multiplex SARS-CoV-2, influenza, and respiratory syncytial virus test.

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe.

Beckman Coulter continues to pay attention to the development of the coagulation market, and recently launched a strategic cooperation with Accurdx in the field of intelligent coagulation, setting another milestone in localization innovation.

Dublin-based diagnostics firm Trinity Biotech on Thursday reported a 61 percent year-over-year increase in second quarter revenues, driven in part by sales of its PCR viral transport media for SARS-CoV-2 testing.

The Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval to the Thermo Fisher Scientific's Oncomine Dx Target Test to be used as a companion diagnostic to identify patients with RET-fusion positive non-small cell lung cancer (NSCLC).

On September 13, 2021, Shanghai Labway Medical Laboratory Co., Ltd. was listed on Shenzhen Stock Exchange (SZSE) ChiNext. Stock code: 688622. The number of new shares publicly issued this time is 48.062 million shares, the issue price is CNY4.17/share, and the opening price is CNY18.25/share.